SUPPLEMENTARY INFORMATION S3
(A) Specificity of phospho-p27 kip1 S10 antibody as demonstrated from the western blot. Two cell lines were chosen for this assay -K562 having majorly cytosolic p27 kip1 and AGS having majorly nuclear p27 kip1 . Cells were subjected to sub-cellular fractionation and total p27 kip1 levels and phospho-p27 kip1 S10 was probed using respective antibodies in each fraction. Purity of the fractions was assessed by nuclear Lamin and cytoplasmic GAPDH levels in both the fractions.
(B) Immuno-cytochemistry based imaging of p27 kip1 in K562 cells treated with/without imatinib. (H) K562 cells were treated with imatinib with the indicated dose (in µM) for 24 hr and the levels of ROCK1 and ROCK2 was assessed by western blotting. Beta actin was used as a loading control.
(I) Fibronectin adhesion assay: CD34 + cells isolated from chronic CML patient was nucleofected with the various constructs of p27 and their adherence to fibronectin matrix was assayed in triplicate. Data represents fold change in cellular adhesion to fibronectin normalised against control CD34 + cells.
(J) Transwell migration assay: CD34 + cells isolated from chronic CML patient was nucleofected with the various constructs of p27 and their migration through the 3µ pore was assayed in triplicate. Data represents percentage of transfected cells which have migrated to the lower chamber with respect to control CD34 + cells.
(K) K562 cells were transfected with GFP tagged MOCK, RhoAN19 or RhoAL63 vectors followed by treatment with/without 1µM imatinib for 24 hr. Cells were stained with anti cytochrome c antibody (red) and observed under the confocal microscope for diffused cytochrome c staining indicating release of cytochrome c from the mitochondria. 100 cells were observed in three independent preparations and the mean ± SEM was plotted. (p<0.005) (L) K562 cells were transfected with MOCK, RhoAN19 or RhoAL63 vectors followed by treatment with/without 1µM imatinib. Cytochrome c released from the mitochondria was estimated in the purified mitochondria free cytosolic fraction by western blot. Tim23 was used to estimate mitochondrial contamination in the cytosolic preparations (densitometric estimation given in parenthesis) while beta actin was used as a loading control. (n=3, p<0.019) (P) Densitometric analysis of the western blots (Fig. 5C) showing the change in expression of phospho-c-jun and c-jun in the presence of imatinib or C3 exozyme or both. Normalised densitometric expression values were plotted against the expression seen in untreated K562 cells. (n=3, *p<0.016, **p<0.003) (Q) K562 cells were treated with SP600125, imatinib or both. Cytochrome c released from the mitochondria was estimated in the purified mitochondria free cytosolic fraction by western blot (Fig. 5D ). Tim23 was used to estimate mitochondrial contamination in the cytosolic preparations while beta actin was used as a loading control. (n=3,p<0.008)
